The FDA orders a nationwide recall of certain thyroid tablets after it determines the affected product lot may be overstrength, which the agency describes as potentially “superpotent.” The recall covers patients using the specific lot identified by the FDA, and the warning applies to the product’s current distribution.
The FDA advises patients not to stop taking the medication on their own. Instead, it recommends that patients who have the recalled tablets contact their health care provider for guidance before making any changes to their treatment. The guidance aims to ensure patients can continue appropriate thyroid therapy while the issue is addressed.
Both outlets reference the same FDA action and rationale, but differ mainly in how they frame the concern and advise affected patients. The Hill emphasizes the nationwide nature of the recall and the “superpotency” description, while the other outlet largely reiterates the FDA’s notice.
